CLINICAL TRIALS PROFILE FOR BRENTUXIMAB VEDOTIN
✉ Email this page to a colleague
All Clinical Trials for brentuximab vedotin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00430846 ↗ | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | Completed | Seagen Inc. | Phase 1 | 2006-11-01 | Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. |
| NCT00430846 ↗ | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | Completed | Seattle Genetics, Inc. | Phase 1 | 2006-11-01 | Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. |
| NCT00649584 ↗ | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | Terminated | Seagen Inc. | Phase 1 | 2008-03-01 | This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients. |
| NCT00649584 ↗ | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | Terminated | Seattle Genetics, Inc. | Phase 1 | 2008-03-01 | This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients. |
| NCT00848926 ↗ | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | 2009-02-01 | This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma. |
| NCT00848926 ↗ | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | Completed | Seagen Inc. | Phase 2 | 2009-02-01 | This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for brentuximab vedotin
Condition Name
Clinical Trial Locations for brentuximab vedotin
Trials by Country
Clinical Trial Progress for brentuximab vedotin
Clinical Trial Phase
Clinical Trial Sponsors for brentuximab vedotin
Sponsor Name
